Lucy Scientific Discovery Inc. Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)’
By ’
Vancouver, British Columbia’ ’ Lucy Scientific Discovery Inc. (NASDAQ: LSDI), a company dedicated to advancing the understanding and applications of psychotropic medicines, improving mental health outcomes, and enhancing well-being for individuals worldwide, has received a notification from Nasdaq regarding its non-compliance with Listing Rule 5250(c)(1).
The Nasdaq Listing Rule 5250(c)(1) pertains to the timely filing of periodic financial reports with the Securities and Exchange Commission (SEC). Non-compliance with this rule raises concerns about the company’s adherence to regulatory standards that ensure transparency and protect investor interests.
Lucy Scientific Discovery Inc. has announced that it will appear before a Nasdaq Hearings Panel (the Panel) on June 25, 2024. The hearing will examine the company’s proposed plan to regain compliance, specifically focusing on Nasdaq Listing Rule 5550(b), commonly known as the Stockholders Equity Rule.
The Stockholders Equity Rule stipulates that listed companies must maintain a minimum threshold of stockholders’ equity or meet specific market value or net income standards. Failure to meet these requirements can result in delisting from the Nasdaq.
As Lucy Scientific Discovery Inc. continues its mission of advancing psychotropic medicine research and improving mental health outcomes globally, this upcoming hearing will be a significant event. The company’s proactive steps to address regulatory requirements will be closely monitored by stakeholders, investors, and industry observers.
A successful hearing outcome will be crucial for Lucy Scientific Discovery Inc. to maintain its listing on the Nasdaq and continue its research and development efforts without interruption.
The forthcoming period will be critical for the company as it navigates these challenges and seeks to assure the market of its compliance and commitment to transparency and adherence to financial reporting standards.This article outlines the facts and context surrounding Lucy Scientific Discovery Inc.’s receipt of a non-compliance notice from Nasdaq and its scheduled hearing with a Nasdaq Hearings Panel to address the issue.
Comments